These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19486027)

  • 41. Systemic reactions to inhalant immunotherapy using 1:1 target dosing.
    Holland CL; Samuels KM; Baldwin JL; Greenhawt MJ
    Ann Allergy Asthma Immunol; 2014 May; 112(5):453-8. PubMed ID: 24631183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine.
    Phillips JF; Lockey RF; Fox RW; Ledford DK; Glaum MC
    Allergy Asthma Proc; 2011; 32(4):288-94. PubMed ID: 21781404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing the safety of subcutaneous immunotherapy dose adjustments.
    Webber CM; Calabria CW
    Ann Allergy Asthma Immunol; 2010 Nov; 105(5):369-75. PubMed ID: 21055663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allergy immunotherapy safety: location matters!
    Cox L; Aaronson D; Casale TB; Honsinger R; Weber R
    J Allergy Clin Immunol Pract; 2013; 1(5):455-7. PubMed ID: 24565616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors.
    Rank MA; Oslie CL; Krogman JL; Park MA; Li JT
    Allergy Asthma Proc; 2008; 29(4):400-5. PubMed ID: 18702889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fear of repeated injections in children younger than 4 years receiving subcutaneous allergy immunotherapy.
    de Vos G; Shankar V; Nazari R; Kooragayalu S; Smith M; Wiznia A; Rosenstreich D
    Ann Allergy Asthma Immunol; 2012 Dec; 109(6):465-9. PubMed ID: 23176889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective study of tolerance to short initiation schedules in subcutaneous immunotherapy.
    Gandarias B; Alonso MD; Fernández Rivas M; Fernández-Távora L; Miranda P; Muñoz Lejarazu D; Sotillo M; Tejero J; Rico P
    J Investig Allergol Clin Immunol; 2005; 15(4):242-8. PubMed ID: 16433204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study on immunotherapy safety: clinical practice in allergy outpatient care].
    Tomás-Pérez M; González-Cavero L; Domínguez-Ortega J
    Rev Alerg Mex; 2018; 65(4):357-361. PubMed ID: 30602205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of systemic reactions in rush, cluster, and standard-build aeroallergen immunotherapy.
    Winslow AW; Turbyville JC; Sublett JW; Sublett JL; Pollard SJ
    Ann Allergy Asthma Immunol; 2016 Nov; 117(5):542-545. PubMed ID: 27788885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The perception of allergen-specific immunotherapy among Italian general practitioners.
    Lombardi C; Bettoncelli G; Canonica GW; Passalacqua G
    Eur Ann Allergy Clin Immunol; 2012 Apr; 44(2):80-2. PubMed ID: 22768727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of anaphylaxis in cluster vs standard subcutaneous multiallergen immunotherapy.
    Chen JH; Orden T; Wang J; Sowho M; Tversky J
    Ann Allergy Asthma Immunol; 2023 May; 130(5):622-627. PubMed ID: 36521783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic reactions occurring during immunotherapy with standardized pollen extracts.
    Hejjaoui A; Ferrando R; Dhivert H; Michel FB; Bousquet J
    J Allergy Clin Immunol; 1992 May; 89(5):925-33. PubMed ID: 1583250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life.
    Caminati M; Arcolaci A; Guerriero M; Manzotti G; Crivellaro M; Rolla G; Fassio F; Senna G
    Immunotherapy; 2019 Jun; 11(9):783-794. PubMed ID: 31094255
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of immunotherapy on Thai asthmatic children.
    Choovoravech P
    Asian Pac J Allergy Immunol; 1984 Jun; 2(1):32-6. PubMed ID: 6529481
    [No Abstract]   [Full Text] [Related]  

  • 55. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions.
    Tinkelman DG; Cole WQ; Tunno J
    J Allergy Clin Immunol; 1995 Jan; 95(1 Pt 1):8-14. PubMed ID: 7822668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Use of specific immunotherapy in the Basic Health Area of Campiña Sur (Moguer-Huelva)].
    Atienza Martín FJ; Márquez Ramírez P; Pérez Jigato R; Pérez Errazquin I; Alonso Pérez M; López Bueno N
    Aten Primaria; 2000; 26(3):169-71. PubMed ID: 10996950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seventh world congress on vaccines, immunisation and immunotherapy.
    Kurstak E
    Hum Vaccin; 2011; 7 Suppl():1. PubMed ID: 21546792
    [No Abstract]   [Full Text] [Related]  

  • 58. Letter from the editor.
    Ellis RW; Riedmann EM
    Hum Vaccin; 2011; 7 Suppl():2-3. PubMed ID: 21546793
    [No Abstract]   [Full Text] [Related]  

  • 59. Allergy injection at home.
    Anand SC
    Ann Allergy Asthma Immunol; 1996 Jul; 77(1):82. PubMed ID: 8705644
    [No Abstract]   [Full Text] [Related]  

  • 60. Tolerance of needleless subcutaneous immunotherapy in children.
    Traina G; De Vuono A; Valluzzi R; Fierro V; Dahdah L; Artesani MC; Martelli A; Fiocchi A
    Pediatr Allergy Immunol; 2020 Jul; 31(5):582-585. PubMed ID: 32058608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.